|Dr. Ernest Loumaye||Co-Founder, CEO & Director||N/A||N/A||1952|
|Mr. Timothy M. Adams||Chief Financial Officer||N/A||N/A||1960|
|Dr. Jean-Pierre Gotteland Ph.D.||Chief Scientific Officer and Head of R&D||N/A||N/A||1965|
|Mr. Mario Vincent Corso||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Ms. Delphine Renaud||Personal Assistant to the CSO and Head of R&D||N/A||N/A||N/A|
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
ObsEva SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.